Christopher M. Holman

University of Missouri - Kansas City School of Law

Professor of Law

5100 Rockhill Road

Kansas City, MO 64110-2499

United States

SCHOLARLY PAPERS

58

DOWNLOADS
Rank 6,197

SSRN RANKINGS

Top 6,197

in Total Papers Downloads

7,578

SSRN CITATIONS
Rank 31,174

SSRN RANKINGS

Top 31,174

in Total Papers Citations

5

CROSSREF CITATIONS

19

Scholarly Papers (58)

1.

The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation

UMKC Law Review, Vol. 76, p. 295, 2007
Number of pages: 67 Posted: 11 Feb 2008 Last Revised: 26 Mar 2013
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1,646 (11,228)

Abstract:

Loading...

patents, gene, DNA, biologics, biotechnology, genetic testing, forensics, diagnostic testing, biomedical research, research tool, patent litigation, patent infringement

2.

Is Lilly Written Description a Paper Tiger?: A Comprehensive Assessment of the Impact of Eli Lilly and its Progeny in the Courts and Pto

Albany Law Journal of Science and Technology, Vol. 17, 2007
Number of pages: 93 Posted: 18 Oct 2006
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 658 (42,898)

Abstract:

Loading...

Eli Lilly, Enzo, Written Description, patent, biotechnology, lizardtech, Falkner, enablement, DNA, proteins

3.

Do Reverse Payment Settlements Violate the Antitrust Laws?

Santa Clara Computer and High Technology Law Journal, Vol. 23, p. 489, 2007
Number of pages: 99 Posted: 30 May 2007
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 542 (55,158)

Abstract:

Loading...

patent, hatch-waxman, generic drugs, antitrust, reverse payment, settlement, exclusion payment, pharmaceutical, paragraph IV certification

4.

Will Gene Patents Derail the Next-Generation of Genetic Technologies?: A Reassessment of the Evidence Suggests Not

80 UMKC L. REV. 563 (2012).
Number of pages: 44 Posted: 08 Feb 2012 Last Revised: 05 Apr 2013
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 392 (81,854)
Citation 3

Abstract:

Loading...

gene patents, genetic technology, genome sequencing, genetic testing, human genes, biotechnology, patents, patent law, gene patents, DNA patents, biotechnology, genetic testing, diagnostic testing, whole genome sequencing, patent thicket

5.

Bilski: Assessing the Impact of a Newly Invigorated Patent Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine

Christopher M. Holman, Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine, 10 CURRENT TOPICS IN MEDICINAL CHEMISTRY 1937 (2010).
Number of pages: 13 Posted: 23 Jun 2009 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 365 (88,929)

Abstract:

Loading...

Patents, Biotechnology, drugs, Bilski, patent eligibility, patentable subject matter, Labcorp, personalized medicine, diagnostics

6.

Gene Patents Under Fire: Weighing the Costs and Benefits

Christopher M. Holman, Gene Patents under Fire: Weighing the Costs and Benefits, book chapter in BIOTECHNOLOGY AND SOFTWARE PATENT LAW: A COMPARATIVE REVIEW ON NEW DEVELOPMENTS, edited by Emanuela Arezzo and Gustavo Ghidini, Edward Elgar Publishing (2011).
Number of pages: 28 Posted: 17 Nov 2010 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 348 (93,917)

Abstract:

Loading...

Myriad, ACLU, patents, patent law, patent eligibility, patentable subject matter, gene patents, DNA patents, biotechnology, Section 101, BRCA, genetic testing, diagnostic testing

7.

Copyright for Engineered DNA: An Idea Whose Time Has Come?

Christopher M. Holman, Copyright for Engineered DNA: An Idea Whose Time Has Come, 113 W. VA. L. REV. 699 (2011).
Number of pages: 40 Posted: 17 Nov 2010 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 304 (109,030)
Citation 3

Abstract:

Loading...

Synthetic biology, biotechnology, intellectual property, copyright, patent, engineered genetic sequence, engineered DNA

8.

Will Gene Patents Impede Whole Genome Sequencing?: Deconstructing the Myth that 20% o the Human Genome Is Patented

Christopher M. Holman, Will Gene Patents Impede Whole Genome Sequencing?: Deconstructing the Myth That 20% of the Human Genome Is Patented, 2 IP THEORY 1 (2011).
Number of pages: 15 Posted: 25 Jul 2011 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 277 (120,403)
Citation 2

Abstract:

Loading...

patents, patent law, gene patents, DNA patents, biotechnology, genetic testing, diagnostic testing, whole genome sequencing, patent thicket

9.

Biotechnology's Prescription for Patent Reform

Review of Intellectual Property Law, Vol. 5, p. 318, 2006
Number of pages: 31 Posted: 22 Sep 2006
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 273 (122,188)

Abstract:

Loading...

biotechnology, patent, H.R. 2795, patent reform, pharmaceutical, drug, reform, smith, congress, testimony, hearing

10.

Protein Similarity Score: A Simplified Version of the Blast Score as a Superior Alternative to Percent Identity for Claiming Genuses of Related Protein Sequences

Santa Clara Computer & High Technology Law Journal, Vol. 21, p. 55, 2004
Number of pages: 45 Posted: 01 Oct 2006
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 261 (128,181)

Abstract:

Loading...

biotechnology, BLAST, similarity, patents, written description, enablement, percent identity, similarity score, proteins, DNA, sequence

11.

Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents

Joshua D. Sarnoff & Christopher M. Holman, Recent Developments Affecting the Enforcement, Procurement, and Licensing of Research Tool Patents, 23 BERKELEY TECH. L.J. 1299 (2008).
Number of pages: 68 Posted: 10 Apr 2008 Last Revised: 18 Feb 2015
Joshua D. Sarnoff and Christopher M. Holman
DePaul University College of Law and University of Missouri - Kansas City School of Law
Downloads 228 (146,611)
Citation 2

Abstract:

Loading...

patent, research tool, experimental use, regulatory approval, compulsory licensing, exceptions and limitations, licensing, enforcement, patentability

12.

Learning from Litigation: What Can Lawsuits Teach Us About the Role of Human Gene Patents in Research and Innovation?

Kansas Journal of Law & Public Policy, Vol. 18, p. 215, 2009
Number of pages: 52 Posted: 01 Sep 2009 Last Revised: 30 Mar 2013
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 201 (165,021)

Abstract:

Loading...

patents, gene, DNA, biologics, biotechnology, genetic testing, forensics, diagnostic testing, biomedical research, research tool, patent litigation, patent infringement, patent thicket, anticommons, university patenting, gene patents, DNA micro-array

13.

Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics

Christopher M. Holman, Maintaining Incentives for Healthcare Innovation: A Response to the FTC's Report on Follow-On Biologics, 11 MINN. J.L. SCI. & TECH. 755 (2010).
Number of pages: 46 Posted: 02 Oct 2009 Last Revised: 18 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 177 (185,155)

Abstract:

Loading...

follow-on biologics, biosimilars, biogenerics, biologic drugs, Hatch-Waxman, FTC, patents, biotechnology, FDA, data exclusivity

14.

Response to ‘Pervasive Sequence Patents Cover the Entire Human Genome’

Genome Medicine, Vol. 6, No. 14, 2014, George Mason Law & Economics Research Paper No. 14-07, San Diego Legal Studies Paper No. 14-148, Loyola-LA Legal Studies Paper No. 2014-19, Georgia State University College of Law, Legal Studies Research Paper No. 2014-16
Number of pages: 4 Posted: 01 Mar 2014 Last Revised: 14 May 2014
West Virginia University College of Law, University of Missouri - Kansas City School of Law, George Mason University - Antonin Scalia Law School, Faculty, University of San Diego School of Law, Villanova University Charles Widger School of Law, University of Utah - S.J. Quinney College of Law, Georgia State University College of Law, University of Baltimore - School of Law and Loyola Law School Los Angeles
Downloads 173 (188,868)
Citation 1

Abstract:

Loading...

gene patents, human genome, Myriad Genetics, patent claims, patent scope

15.

In Defense of Secondary Pharmaceutical Patents: A Response to the UN's Guidelines for Pharmaceutical Patent Examination

Indiana Law Review, Forthcoming
Number of pages: 56 Posted: 04 Sep 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 162 (199,811)

Abstract:

Loading...

Secondary Pharmaceutical Patents, Guidelines for Pharmaceutical Patent Examination, Patents, Pharmaceutical Patents, Drug Patents

16.

Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine

Christopher M. Holman, Mayo, Myriad, and the Future of Innovation in Molecular Diagnostics and Personalized Medicine, 15 North Carolina Journal of Law and Technology 639 (2014).
Number of pages: 40 Posted: 17 Apr 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 162 (199,811)

Abstract:

Loading...

Mayo, Prometheus, gene patents, Myriad, patent eligibility, patentable subject matter, molecular diagnostics, personalized medicine

17.

The Perils of Taking Property Too Far

Stanford Journal of Law, Science and Policy, Vol. 46, 2009
Number of pages: 19 Posted: 27 May 2009 Last Revised: 14 Nov 2012
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Alberta - Faculty of Public Health, University of Missouri - Kansas City School of Law, affiliation not provided to SSRN, Duke University, Fuqua School of Business-Economics Group and Arizona State University (ASU) - School for the Future of Innovation in Society
Downloads 157 (205,172)

Abstract:

Loading...

biobank, biobanks, genetic testing, genomic testing, Canavan, Myriad, BRCA, research ethics, gene patents, genes, patents, ethics, business models, public health care, clinicial genetics

18.

Developments in Synthetic Biology are Altering the IP Imperatives of Biotechnology

17 Vanderbilt J. Ent. & Tech. L. 385 (2015).
Number of pages: 78 Posted: 27 Jun 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 146 (217,914)
Citation 1

Abstract:

Loading...

Patents, intellectual property, biotechnology, synthetic biology

19.

The Role of Objective Indicia in Assessing the Nonobviousness of Pharmaceutical Inventions

37 Biotechnology Law Report 4 (2018)
Number of pages: 30 Posted: 08 Feb 2019
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 108 (273,626)

Abstract:

Loading...

nonobviousness, patent, pharmaceuticals, objective indicators, objective indicia, secondary considerations

20.

Are Engineered Genetic Sequences Copyrightable?: The U.S. Copyright Office Addresses a Matter of First Impression

35 Biotechnology Law Report 103 (2016)
Number of pages: 21 Posted: 02 Oct 2016
Christopher M. Holman, Claes Gustafsson and Andrew W. Torrance
University of Missouri - Kansas City School of Law, Independent and University of Kansas - School of Law
Downloads 96 (296,144)

Abstract:

Loading...

Copyright, Copyright Office, Copyright Registration, DNA Copyright, Gene Copyright, Synthetic Biology, Biotechnology, Genetic Engineering

21.

Patent Eligibility Post-Myriad: A Reinvigorated Judicial Wildcard of Uncertain Effect

George Washington Law Review, Vol. 82, No. 1796, 2014
Number of pages: 36 Posted: 20 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 83 (324,459)

Abstract:

Loading...

Patent eligibility, Prometheus, Mayo, Myriad, patentable subject matter

22.

Caught between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators after Mayo and Myriad

Christopher M. Holman, Caught Between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators After Mayo and Myriad, 33 BIOTECHNOLOGY LAW REPORT 135 (2014).
Number of pages: 4 Posted: 20 Feb 2015 Last Revised: 21 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 81 (329,315)

Abstract:

Loading...

Divided infringement, joint infringement, Muniauction, Limelight, Akamai, personalized medicine, genetic testing, molecular diagnostics, induced infringement, indirect patent infringement

23.

Bowman v. Monsanto Co.: A Bellwether for the Emerging Issue of Patentable Self-Replicating Technologies and Inadvertent Infringement

Missouri Law Review, Vol. 80, 2015
Number of pages: 59 Posted: 12 Feb 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 65 (371,967)

Abstract:

Loading...

Patents, Self-replicating technology, DNA, biotechnology, self-replication, bowman, Monsanto, agriculture, seeds patents

24.

The Critical Role of Patents in the Development, Commercialization and Utilization of Innovative Genetic Diagnostic Tests and Personalized Medicine

Boston University journal of Science and Technology Law, Vol. 21, No. 2, 2015
Number of pages: 20 Posted: 12 Feb 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 62 (381,117)

Abstract:

Loading...

patents, innovation, biotechnology, diagnostics, personalized medicine, Myriad, Mayo, Prometheus, genetics

25.

Book Review: Patent Ethics: Prosecution, by David Hricik & Mercedes Meyers

The IP Law Book Review, Vol. 1, No. 1, pp 40-45, June 2010
Number of pages: 7 Posted: 09 Oct 2010
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 58 (393,797)

Abstract:

Loading...

Patents, Patent Law, Patent Prosecution, Patent Ethics, Legal Ethics, Professional Responsibility, PTO, Patent And Trademark Office, PTO Code of Professional Conduct, Model Rules of Professional Conduct, Model Code of Professional Responsibility

26.

Ajinomoto v. ITC, the Doctrine of Equivalents, and Biomolecule Claim Limitations at the Federal Circuit

Biotechnology Law Report, 2020
Number of pages: 25 Posted: 28 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 57 (397,135)

Abstract:

Loading...

Ajinomoto, patents, biotechnology, biomolecules, DNA, proteins, doctrine of equivalents, prosecution history estoppel

27.

Charting the Contours of a Copyright Regime Optimized for Engineered Genetic Code

Oklahoma Law Review
Number of pages: 63 Posted: 04 Sep 2016
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 57 (397,135)
Citation 1

Abstract:

Loading...

Copyright, biotechnology, DNA, genetic code, synthetic biology

28.

Patent Eligibility as a Policy Lever to Regulate the Patenting of Personalized Medicine

Christopher M. Holman, Patent Eligibility as a Policy Lever to Regulate the Patenting of Personalized Medicine, book chapter in PERSPECTIVES ON PATENTABLE SUBJECT MATTER, edited by Michael Abramowicz, F. Scott Kieff and James E. Daily, Cambridge University Press (2014).
Number of pages: 32 Posted: 20 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 57 (397,135)

Abstract:

Loading...

Patent eligibility, Prometheus, Mayo, Bilski, personalized medicine, diagnostics, diagnostic testing, molecular diagnostics, genetic testing, patentable subject matter

29.

Supreme Court Asked to Consider Role of Post-Filing Evidence in Assessing Obviousness of Pharmaceutical Inventions

34 Biotechnology L. Rep. 49 (2015).
Number of pages: 4 Posted: 27 Jun 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 56 (400,551)

Abstract:

Loading...

Patents, Nonobviousness, Pharmaceutical Patents, Drug Patents

30.

How Real is the Concern that Seed Patents Will Turn Farmers into Inadvertent Infringers?

Christopher M. Holman, How Real Is the Concern that Seed Patents Will Turn Farmers into Inadvertent Infringers?, 33 BIOTECHNOLOGY LAW REPORT 165 (2014).
Number of pages: 6 Posted: 20 Feb 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 56 (400,551)

Abstract:

Loading...

Bowman, Monsanto, genetically modified crops, agricultural biotechnology, inadvertent infringement, inadvertent patent infringement, patent exhaustion, seed patent

31.

Misplaced Fears in the Battle Over Affordable Biotech Drugs

50 IDEA 565 (2010)
Number of pages: 27 Posted: 21 Mar 2015
David E. Adelman and Christopher M. Holman
University of Texas School of Law and University of Missouri - Kansas City School of Law
Downloads 48 (428,656)

Abstract:

Loading...

follow-on biologics, biogenerics, biologics, patents, FDA, health care reform

32.

Do Biotech Patent Lawsuits Really 'Overwhelmingly Lose?': A Response to Our Divided Patent System

34 Biotechnology L. Rep. 59 (2015).
Number of pages: 9 Posted: 27 Jun 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 46 (436,333)

Abstract:

Loading...

patents, biotechnology, patent litigation, patent empirical studies

33.

Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation

Missouri Law Review, Vol. 76, p. 645, 2011
Number of pages: 49 Posted: 21 Mar 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 38 (469,198)

Abstract:

Loading...

Patents, patent policy, pharmaceutical patents, drug patents, pharmaceutical innovation

34.

Congress Should Decline Ill-Advised Legislative Proposals Aimed at Evergreening of Pharmaceutical Patent Protection

The University of the Pacific Law Review, 2020
Number of pages: 30 Posted: 03 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 20 (566,153)

Abstract:

Loading...

patents, pharmaceuticals, drugs, legislation, evergreening, prduct hopping, patent thicketing

35.

Patentability Standards for Follow-On Pharmaceutical Innovation

37 BIOTECHNOLOGY LAW REPORT 131 (2018)
Number of pages: 31 Posted: 31 Jul 2018 Last Revised: 06 May 2020
Christopher M. Holman, Timo Minssen and Eric M. Solovy
University of Missouri - Kansas City School of Law, University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law and Sidley Austin LLP
Downloads 19 (572,696)
Citation 1

Abstract:

Loading...

UNDP, Patentability Guidelines, Patent Examination, Pharmaceutical Patents, TRIPS Agreement

36.

The Role of Patent Eligibility in Policing Claim Scope

1 IP Theory 56 (2011)
Number of pages: 15 Posted: 21 Mar 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 16 (591,878)

Abstract:

Loading...

Bilski, patent eligibility, patentable subject matter

37.

Helsinn v. Teva: Lingering Ambiguity after the U.S. Supreme Court Holds the AIA Did Not Alter the On-Sale Bar to Patentability

Biotechnology Law Report, 2019
Number of pages: 23 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 13 (612,072)

Abstract:

Loading...

patents, biotechnology, pharamceuticals, on-sale bar, AIA, Helsinn

38.

Gilead Sciences Sued for Failing to Bring a Follow-on Version of Truvada to Market Sooner

Biotechnology Law Report, 2019
Number of pages: 15 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 12 (619,128)

Abstract:

Loading...

patents, drugs, antitrust, product hopping, Gilead, Truvada

39.

A Fractured International Response to CRISPR-Enabled Gene Editing of Agricultural Products

38 Biotechnology Law Report 3 (2019).
Number of pages: 54 Posted: 22 Apr 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 11 (626,033)

Abstract:

Loading...

CRISPR, gene editing

40.

Nuvo v. Dr. Reddy and the Patentability of Prophetic Pharmaceutical Inventions Based on Unexplained Inventive Insight

Biotechnology Law Report, 2019
Number of pages: 13 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 10 (632,871)

Abstract:

Loading...

patents, patentability, drugs, written description requirement, inventive concept, Nuvo[comma separated]

41.

The Lilly Written Description Requirement: A Doctrinal Wildcard of Uncertain Effect

Research Handbook on Patent Law & Theory (2nd Edition), ISBN: 978-1-78536-411-2, Edward Elgar, 2019
Number of pages: 33 Posted: 02 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 9 (639,938)

Abstract:

Loading...

patent, biotechnology, written description requirement, Eli Lilly, Ariad, LWD

42.

Recent PTO Guidance Charts a New Course Through the Patent Eligibility Quagmire

Biotechnology Law Report, 2019
Number of pages: 13 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 8 (647,097)

Abstract:

Loading...

patent, patent eligibility, biotechnology, PTO guidance, Patent Office, PTO

43.

Congress Considering Legislation Aimed at Increasing Competition in Pharmaceuticals

Biotechnology Law Report, 2019
Number of pages: 15 Posted: 27 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 6 (661,422)

Abstract:

Loading...

patents, drugs, Congress, legislation, patent reform

44.

The Renewable Fuel Standard Reimagined: Clearing a Path for Truly Advanced Biofuels

86 UMKC L. Rev. 805 (2018)
Number of pages: 50 Posted: 02 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 2 (694,347)

Abstract:

Loading...

renewable fuel standard, biofuels,

45.

Praxair v. Mallinckrodt: An Expanded Interpretation of the Printed Matter Doctrine with Important Implications for Biotechnology

37 BIOTECHNOLOGY LAW REPORT 188 (2018)
Number of pages: 17
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 2

Abstract:

Loading...

Praxair, printed matter doctrine, patent eligibility, patentability, biotechnology

46.

The Mayo Framework Is Bad for Your Health

23 George Mason Law Review 901 (2016)
Number of pages: 40 Posted: 02 Jun 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1 (706,682)

Abstract:

Loading...

patent eligibility, patent, Mayo, biotechnology, diagnostics

47.

A Biotechnology-Centric Look at Fee Shifting in Patent Litigation Post-Octane Fitness

36 BIOTECHNOLOGY LAW REPORT 81 (2017)
Number of pages: 4
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

Octane Fitness, Highmark, attorneys fees, attorney fee-shifting, patent litigation, biotechnology

48.

Congress Considering Legislation Intended to Reverse the Recent Trend toward Devaluation of the U.S. Patent Right

37 BIOTECHNOLOGY LAW REPORT 243 (2018)
Number of pages: 12
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

patents, biotechnology, legislation, patent reform, patent devaluation

49.

Vanda v. West-Ward Pharmaceuticals: Good News for the Patent Eligibility of Diagnostics and Personalized Medicine, with Some Important Caveats

37 BIOTECHNOLOGY LAW REPORT 117 (2018)
Number of pages: 9
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

Vanda, Mayo, patent eligibility, biotechnology, diagnostic test, patentability

50.

Acorda Therapeutics and the Role of Blocking Patents in Assessing Objective Indicia of Nonobviousness in the Pharmaceutical Arts

37 BIOTECHNOLOGY LAW REPORT 305 (2018)
Number of pages: 9
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

patents, obviousness, secondary considerations, objecive indicia, pharmaceuticals, biotechnoogy, Acorda

51.

FDA’s Efforts to Tame the “Wild West” of Regenerative Medicine

36 BIOTECHNOLOGY LAW REPORT 217 (2017)
Number of pages: 6
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

regenerative medicine, FDA, regulation, stem cell treatments

52.

Enablement Invoked as a ‘‘Super-Written Description Requirement’’ to Overturn $2.5 Billion Jury Verdict

37 BIOTECHNOLOGY LAW REPORT 63 (2018)
Number of pages: 5
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

patents, biotechnology, written description, enablement, Idenix

53.

For Monoclonal Antibodies, Compliance with the Written Description Requirement Has Become a Moving Target

36 BIOTECHNOLOGY LAW REPORT 273 (2017)
Number of pages: 11
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

patents, monoclonals, antibodies, biotechnology, written description requirement, biologics

54.

Eli Lilly v. Teva: Generic Companies Infringe under Akamai IV in Case of Divided Infringement

36 BIOTECHNOLOGY LAW REPORT 31 (2017)
Number of pages: 7
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

patent, biotechnology, diagnostics, divided infringement, joint infringement, induced infringement, Akamai

55.

The Supreme Court’s Devaluation of U.S. Patents

36 BIOTECHNOLOGY LAW REPORT 151 (2017)
Number of pages: 16
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 1

Abstract:

Loading...

Sandoz, TC Heartland, Impression Products, patents, Supreme Court, biotechnology

56.

Trend in Human Gene Patent Litigation

Science 322:198-99 (2008)
Posted: 21 Mar 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law

Abstract:

Loading...

patent policy, patents, gene patents, patent litigation

57.

Patent Border Wars: Defining the Boundary between Scientific Discoveries and Patentable Inventions

Trends in Biotechnology, Vol. 25, pp. 539-543, 2007
Posted: 11 Feb 2008
Christopher M. Holman
University of Missouri - Kansas City School of Law

Abstract:

Loading...

patentable subject matter, research tools, genes, patents, gene patents, research tools

58.

Clearing a Path Through the Patent Thicket

Cell, Vol. 125, pp. 629-633, 2006
Posted: 18 Oct 2006 Last Revised: 17 May 2014
Christopher M. Holman
University of Missouri - Kansas City School of Law

Abstract:

Loading...

patents, biotechnology, patent thicket, research tools, research use, Bayh-Dole, upstream patents, junk patents, open source

Other Papers (4)

Total Downloads: 117
1.

Brief of Amici Curiae Interested Patent Law Professors in Support of Neither Party in Prometheus v. Mayo

Federal Circuit Court of Appeals, 2009 WL 462602
Number of pages: 28 Posted: 13 Nov 2009 Last Revised: 05 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 44

Abstract:

Loading...

Prometheus, Mayo, Bilski, patentable subject matter, patent eligibility, diagnostics, personalized medicine, biotechnology

2.

Brief of Amicus Curiae Law Professor Christopher M. Holman in Support of Neither Party in Ariad v. Eli Lilly

Federal Circuit Court of Appeals, 2009 WL 3711551
Number of pages: 42 Posted: 13 Nov 2009 Last Revised: 05 May 2020
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 38

Abstract:

Loading...

Ariad, Eli Lilly, biotechnology, patent law, written description requirement, amicus

3.

On the Question: Is Copyright the Way to Gain Intellectual Property Protection for DNA Sequences?

33 Biotechnology Law Report 139, 2014
Number of pages: 2 Posted: 20 Sep 2014
Christopher M. Holman and Andrew W. Torrance
University of Missouri - Kansas City School of Law and University of Kansas - School of Law
Downloads 28

Abstract:

Loading...

4.

Intellectual Property in the Age of Personal Genomics and Synthetic Biology

Christopher M. Holman, Intellectual Property in the Age of Personal Genomics and Synthetic Biology, 31 BIOTECHNOLOGY LAW REPORT 1 (2012).
Number of pages: 2 Posted: 17 Apr 2015
Christopher M. Holman
University of Missouri - Kansas City School of Law
Downloads 7

Abstract:

Loading...

patents, intellectual property, biotechnology, genomics, synthetic biology, genetic testing, diagnostic testing